Article thumbnail

Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia

By Grzegorz Helbig, Andrzej Moskwa, Marek Hus, Jarosław Piszcz, Alina Swiderska, Alina Urbanowicz, Małgorzata Całbecka, Ilona Seferyńska, Małgorzata Raźny, Marek Rodzaj, Ewa Żuk and Sławomira Kyrcz-Krzemień
Topics: Letter to the Editor
Publisher: Springer-Verlag
OAI identifier: oai:pubmedcentral.nih.gov:3064899
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2003). A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
  2. Berthaud P et al (2005) Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Ther Drug Monit 27:634–640
  3. (2004). Clinical and molecular features of FIP1L1-PDGFRA (?) chronic eosinophilic leukemia.
  4. et al (2009) FIP1L1-PDGFRa D842 V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGF T674I eosinophilic leukaemia with single agent sorafenib.
  5. Haferlach C et al (2008) Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndromea phase-II study.
  6. (2011). Iacobucci I et al (2009) Chronic eosinophilic leukemia with FIP1L1-PDGFRA rearrangement: the response to imatinib is durable. A report of 33 patients with a follow-up of 30 to 92 months. Blood 114:22 (abstract 3894) Cancer Chemother Pharmacol
  7. (2007). Low-dose imatinib mesylate leads to rapid induction of major molecular response and achievement of complete molecular remission in FIP1L1-PDGFRA positive chronic eosinophilic leukemia.
  8. (2007). Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.
  9. (2007). The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRa positive hypereosinophilic syndrome. Results of a multicenter prospective study.
  10. (2006). The results of imatinib therapy for patients with primary eosinophilic disorders.
  11. (2009). Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1-PDGFRA fusion transcript: ectended follow-up.